|
Monday, March 10, 2008
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
BioLeap
A lab-less drug discovery company
About
|
BioLeap is a lab-less drug discovery company with a capital-efficient development process centered on Computational Fragment-Based Design (CFBD).
CFBD is a fundamental new trend in drug discovery that solves the central problem of gaining access to the huge chemical diversity required to optimize drug compounds. BioLeap's proprietary technology for CFBD uniquely addresses the key limitations of existing methods: predictability of potency, practicality of chemical synthesis, and ease of use by chemists. By exploiting the 3d-structure of proteins, CFBD provides a rational basis for attacking important drug development challenges including side-effects, mutation resistance, and optimization of pharmacologic properties. It offers a new source of novelty in chemistry that is essential for obtaining patents on compounds.
The company's business model is to develop patentable second generation drugs for licensing to the pharmaceutical industry upon conclusion of pre-clinical development. BioLeap's unusually low cost structure derives from CFBD requiring significantly fewer compounds to be made and tested, combined with an aggressive out-sourcing strategy. The emerging market trends for earlier licensing of pre-clinical compounds, coupled with BioLeap's low costs, position the company to achieve higher returns, earlier, compared to traditional bio-tech models.
3 Major Issues
|
- How do we present a compelling view of the value proposition to the industry?
- Who would be the most appropriate targets for this platform? (i.e. target more smaller firms first to build confidence around the concept and then move into larger markets?)
- What pricing models and/or price points make the most sense for this type of platform, and what factors should be taken into account to determine these?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Gerry Evans, EVP, will deliver the Company's "Elevator" Pitch to the Group
8:15 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
